Patents by Inventor Ruye Xing

Ruye Xing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glycopegylated interferon ?
    Patent number: 8268967
    Abstract: The present invention provides IFN-? conjugates including IFN-? peptides and modifying groups such as PEG moieties. The IFN-? peptide and modifying group are linked via an intact glycosyl linking group interposed between and covalently attached to the IFN-? peptide and the modifying group. The IFN-? conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar onto an amino acid or a glycosyl residue on the IFN-? peptide. Also provided are methods for preparing the IFN-? conjugates, methods for treating various disease conditions with the IFN-? conjugates, and pharmaceutical formulations including the IFN-? conjugates.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: September 18, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Henrik Clausen, Ruye Xing
  • Glycopegylated Interferon Alpha
    Publication number: 20090028822
    Abstract: The present invention provides IFN-? conjugates including IFN-? peptides and modifying groups such as PEG moieties. The IFN-? peptide and modifying group are linked via an intact glycosyl linking group interposed between and covalently attached to the IFN-? peptide and the modifying group. The IFN-? conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar onto an amino acid or a glycosyl residue on the IFN-? peptide. Also provided are methods for preparing the IFN-? conjugates, methods for treating various disease conditions with the IFN-? conjugates, and pharmaceutical formulations including the IFN-? conjugates.
    Type: Application
    Filed: September 12, 2005
    Publication date: January 29, 2009
    Applicant: NEOSE TECHNOLOGIES, INC.
    Inventors: Shawn DeFrees, David A. Zopf, Henrik Clausen, Ruye Xing
  • Purified cytokine inhibitory factor
    Patent number: 7083809
    Abstract: Disclosed is a composition comprising a substantially purified Cytokine Inhibitory Factor (CIF) having certain characteristics, including the ability to inhibit RNA transcription of the pro-inflammatory cytokines tumor necrosis factor alpha (TNF-?), interleukin-1-beta (IL-1?), and interleukin-2 (IL-2). Also disclosed is a method for substantially purifying the Cytokine Inhibitory Factor and a method for modulating the immune system of an animal using such composition.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: August 1, 2006
    Assignee: Arkion Life Sciences, LLC
    Inventors: Subramanian Iyer, William L. Johnson, Lance Nguyen, Steven C. Ross, Ruye Xing
  • Immune T-cell stimulation
    Publication number: 20040005327
    Abstract: The present invention is a novel approach for stimulating or enhancing immune T-cells in an animal. In particular, the invention is directed to an egg, and more specifically, a fraction thereof of a size less than 3000 daltons, obtained from an avian that has been hyperimmunized with one or more immunogens. The ingestion by an animal of an effective amount of the hyperimmune egg or fraction thereof causes a significant increase in the overall T-cell population in that animal.
    Type: Application
    Filed: May 15, 2003
    Publication date: January 8, 2004
    Inventors: Subramanian Iyer, Ruye Xing
  • Purified cytokine inhibitory factor
    Publication number: 20030152641
    Abstract: Disclosed is a composition comprising a substantially purified Cytokine Inhibitory Factor (CIF) having certain characteristics, including the ability to inhibit RNA transcription of the pro-inflammatory cytokines tumor necrosis factor alpha (TNF-&agr;), interleukin-1-beta (IL-1&bgr;), and interleukin-2 (IL-2). Also disclosed is a method for substantially purifying the Cytokine Inhibitory Factor and a method for modulating the immune system of an animal using such composition.
    Type: Application
    Filed: February 11, 2003
    Publication date: August 14, 2003
    Inventors: Subramanian Iyer, William L. Johnson, Lance Nguyen, Steven C. Ross, Ruye Xing
  • Highly purified cytokine activating factor and methods of use
    Publication number: 20030143190
    Abstract: Disclosed is an isolated Cytokine Activating Factor (CAF) protein, an isolated nucleic acid molecule encoding a CAF protein, an antibody that selectively binds to a CAF protein, a composition comprising a Cytokine Activating Factor (CAF), and a method for modulating the immune system using the composition. Also disclosed is a method for treating cancer using such a composition.
    Type: Application
    Filed: May 14, 2002
    Publication date: July 31, 2003
    Applicant: DCV, Inc.
    Inventors: Subramanian Iyer, Tay N. Nguyen, Dauh-Rurng Wu, Ruye Xing
  • Highly purified cytokine activating factor and methods of use
    Patent number: 6420337
    Abstract: Disclosed is an isolated Cytokine Activating Factor (CAF) protein, an isolated nucleic acid molecule encoding a CAF protein, an antibody that selectively binds to a CAF protein, a composition comprising a Cytokine Activating Factor (CAF), and a method for modulating the immune system using the composition. Also disclosed is a method for treating cancer using such a composition.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: July 16, 2002
    Assignee: Arkion Life Sciences LLC
    Inventors: Subramanian Iyer, Tay N. Nguyen, Dauh-Rurng Wu, Ruye Xing